Cargando…
The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial
INTRODUCTION: The clinical utility of denosumab for the treatment of glucocorticoid-induced osteoporosis (GIOP) has yet to be established. This study aimed to compare the effects of denosumab on bone mineral density (BMD) and bone turnover markers to those of alendronate in patients with GIOP. METHO...
Autores principales: | Iseri, Ken, Iyoda, Masayuki, Watanabe, Makoto, Matsumoto, Kei, Sanada, Daisuke, Inoue, Takashi, Tachibana, Shohei, Shibata, Takanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854344/ https://www.ncbi.nlm.nih.gov/pubmed/29543887 http://dx.doi.org/10.1371/journal.pone.0193846 |
Ejemplares similares
-
Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy
por: Hihara, Kei, et al.
Publicado: (2016) -
Serum uromodulin is associated with the severity of clinicopathological findings in ANCA-associated glomerulonephritis
por: Tachibana, Shohei, et al.
Publicado: (2019) -
Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy
por: Wada, Yukihiro, et al.
Publicado: (2018) -
Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020) -
A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy
por: Sugiyama, Motonori, et al.
Publicado: (2020)